18 June 2020

Oncode Oncology Bridge Fund appoints Investment Advisory Committee

Elize Brolsma

The Oncode Oncology Bridge Fund provides early stage financing to support the creation and growth of new enterprises based on highly innovative science performed by researchers at the Oncode Institute. We are proud to announce that the Bridge Fund has appointed its Investment Advisory Committee (IAC). The role of the IAC is to review and make recommendations on investment proposals presented by the Fund Managers. Initially it consists of three members and will gradually expand to five members with diverse early-stage venture experience in the field of life sciences. The members of the committee have a mixture of technical, scientific, business, and investment experience in building and growing therapeutics, diagnostics and services focussed oncology companies.

The current initial members of the IAC are:
- Dr. Graeme Smith, CSO Artios Pharma [bio]
- Dr. Tol Trimborn, COO Gadeta [bio]
- Dr. Jan Groen, CEO Intravacc [bio]

Chris De Jonghe, Valorization Director at Oncode, says: “We are very pleased to welcome such skilled talent to our committee. Their knowledge and hands-on experience with the start-up environment will be a tremendous support for Oncode Investigators launching new ventures.”

Find out more about the Oncode Oncology Bridge Fund.

Shobhit Dhawan Fund Manager

Other News

Oncode Coverbeeld Q2 2021
Oncode Digital Magazine - April 2021
Welcome to the April edition of our digital magazine! Discover the latest interviews, science stories, latest updates and much more.
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
Lude and Michiel
Oncode Investigators Michiel Vermeulen and Lude Franke receive Vici grant
Oncode is proud to announce that Oncode Investigators Michiel Vermeulen (Radboudumc) and Lude Franke (UMCG) will both receive the Vici grant of 1.5 million euros from the Dutch Research Council (NWO).
PeterThijssen
Ecto org KRT14
First patient-derived organoid model for cervical cancer
Researchers from the group of Oncode Investigator Hans Clevers (Hubrecht Institute) developed the first patient-derived organoid model for cervical cancer. They also modelled the healthy human cervix using organoids. In close collaboration with the UMC Utrecht, Princess Máxima Center for pediatric oncology and the Netherlands Cancer Institute, the researchers used the organoid-based platform to study sexually transmitted infections for a herpes virus. The model can potentially also be used to study the human papillomavirus (HPV), which is one of the main causes of cervical cancer.
Bianca-OliviaNita